RT期刊文章SR电子T1 ALS患者的语言学习能力(P01.109)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P01.109 OP P0首页1.109 VO 78是1补充A1玛丽亚蔷薇花坛Barulli A1玛丽安娜Tursi A1罗赞娜Tortelli A1罗莎Capozzo A1罗赞娜Cortese A1 Eustachio D 'Errico A1安东尼奥狮子座A1伊莎贝拉西蒙A1吉安卡洛Logroscino年2012 UL //www.ez-admanager.com/content/78/1_Supplement/P01.109.abstract AB目的:研究ALS的神经认知障碍谱系。背景神经认知障碍主要包括执行功能障碍(1)。另一方面,不清楚内存是主要涉及(2).Design /方法:连续55 ALS患者运动NeuronCenter,巴里大学神经学系。首页诊断是基于El堆渣场标准(布鲁克斯,1994)。招募了七十名健康与控制。我们检查了通过雷伊的听觉言语学习记忆能力测试(RAVLT):自由回忆在五个试验,直接和延迟回忆,语言学习,语言遗忘小学和近因效应的分数。所有受试者完成下面的神经心理学电池:迷你精神状态检查(MMSE)、额评估电池(FAB):数字广度向前(DSF);数字广度向后(双边带);注意力矩阵(点);言语流畅性测试(音频电报);Stroop测试(ST);乌鸦的彩色矩阵(RCM)。Results: we enrolled 33 men and 22 women in ALS group (age 59.7±9.7; educational level 9.6±4.1 yrs; disease duration at baseline 30.9±32.1 months; ALSFRS-r 37.8±6.2; FVC 92.5±22.7; MMT 8.1±1.3). Compared with controls, ALS patients performed worse on the recall immediate (p=.007). The recency and primary effect was less evident in ALS than control group (p=.018; p=.004). Moreover, the ALS group performed worse on short-term memory (DSF, p=.005), working memory (DSB, p=.000), verbal fluency (VFT, p=.000), flexibility (RCM, p=.025) and general cognitive abilities (MMSE, p=.001; FAB, p=.009). The different indices of RAVLT showed a significant correlation with all executive measures in ALS group.Conclusions: ALS patients present impairment of both executive and memory dysfunctions. The executive dysfunctions are primary involved with failure of elaborative encoding and strategic retrieval processing, as a consequence of verbal learning identified by free recall, recency and primary effect scores. On the other hand, storage processes, a main component of memory, are intact.Disclosure: Dr. Barulli has nothing to disclose. Dr. Tursi has nothing to disclose. Dr. Barulli has nothing to disclose. Dr. Capozzo has nothing to disclose. Dr. Barulli has nothing to disclose. Dr. D'Errico has nothing to disclose. Dr. Leo has nothing to disclose. Dr. Simone has received personal compensation for activities with Sanofi-Aventis and Biogen Idec. Dr. Logroscino has received personal compensation for activities with Novartis, Glaxo and Boerhinger.Monday, April 23 2012, 14:00 pm-18:30 pm